Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine Conditioning for Poor Risk AML
NCT02252107Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2014
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML), sponsored by Radboud University Medical Center. Primary endpoint: Relapse at 1-year after the transplantation procedure. Started Oct 2014; status: completed.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02252107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02252107.